Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Convatec shares rise as increases sales outlook as growth accelerates

18th Nov 2026 09:30

(Alliance News) - Convatec Group PLC on Tuesday raised full-year sales guidance as growth accelerated in the second half of the financial half with Infusion Care and Continence Care outperforming.

In response, shares in the London-based medical products company shot up 8.9% to 268.80 pence each in London on Wednesday, the best performer in the FTSE 100 index, which was down 0.3%.

Convatec now expects full-year revenue growth, excluding wound care treatment InnovaMatrix, of 6.25% to 7.00% compared to USD2.44 billion in 2025, the guidance raised from 5.50% to 6.50% before.

In a trading update, Convatec reported 10-month organic revenue growth of 6.6%, or 3.7% including InnovaMatrix.

InnovaMatrix has been hit by uncertainty regarding Medicare reimbursement coverage in the US for specific, high-volume wound treatments. Sales of InnovaMatrix slumped 30% to USD69 million in 2025.

On Wednesday, Convatec said it expects 2026 revenue of just USD5 million from InnovaMatrix compared to prior guidance of USD5 to USD10 million.

Offsetting this, the company raised its outlook in its Continence Care and Infusion Care divisions.

Continence Care has accelerated to mid-to-high-single-digit percentage growth year-to-date, reflecting increased US new patient volumes and further strong growth outside the US, Convatec said. As a result, Convatec now expects mid-to-high-single-digit growth at constant currency in 2026 compared to mid-single-digit growth before.

Infusion Care has accelerated to double-digit percentage growth year-to-date, driven by faster second-half diabetes growth and continued strong growth in AbbVie Inc's treatment of Parkinson's disease. Convatec now expects double-digit growth in 2026 compared to high single digit growth previously.

It continues to expect mid-single digit growth in Ostomy Care for the full-year.

In addition, Convatec continues to forecast adjusted operating profit margin of at least 23% and double-digit percentage growth in adjusted EPS. It sees capital expenditure at the upper end of the USD200 to USD230 million range.

Medium-term targets for 6% to 8% organic revenue growth and double-digit adjusted EPS growth are unchanged.

Chief Executive Jonny Mason said: "Revenue growth has accelerated in the second half, as we expected. We saw notable strength in Infusion Care, where improved execution enabled us to meet rising demand, ahead of new capacity coming online in 2027. Overall, we continued to gain share in all categories, underpinned by new product launches."

By Jeremy Cutler, Alliance News reporter

Comments and questions to [email protected]

Copyright 2026 Alliance News Ltd. All Rights Reserved.


Related Shares:

ConvaTec
FTSE 100 Latest
Value10,452.68
Change-98.49